Latest Content

Talzenna Plus Xtandi May Improve Survival in mCRPC

February 13th 2025, 3:10pm

By Jordyn Sava

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.

Breaking Down the Implications of Calquence Combination Therapy in MCL

February 13th 2025, 2:00pm

By Dr. Tycel Phillips

Video

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously untreated mantle cell lymphoma.

Phase 2 Trial of Firi-Cel CAR T-Cell Therapy Discontinued in Lymphoma

February 12th 2025, 10:00pm

By Ryan Scott

Article

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been discontinued.

GI Bleeding Significantly Impacts GIST Treatment Outcomes

February 12th 2025, 8:00pm

By Ryan Scott

Article

The prognosis of patients with gastrointestinal stromal tumors is significantly impacted by gastrointestinal bleeding.

Moving Slower and Slower After Myelodysplastic Syndrome

February 12th 2025, 6:00pm

By Jane Biehl Ph.D.

Article

I have been frustrated lately by my increasing slowness following an blood cancer diagnosis, which has become noticeable to others.

Empowering Patients and Advocating For Yourself After Cervical Cancer

February 12th 2025, 5:00pm

By Dr. Ritu Salani

Video

Dr. Ritu Salani discusses how patients with cervical cancer can advocate for their health and collaborate with their medical team to ensure the best care.

FDA Approves Adcetris With Revlimid and Rituxan For R/R LBCL

February 12th 2025, 3:16pm

By Alex Biese

Article

The FDA has approved Adcetris plus Revlimid and Rituxan in adults with relapsed or refractory large B-cell lymphoma.

An Expert Explains the Enhertu Approval in HER2-Low and -Ultralow Breast Cancer

February 12th 2025, 2:00pm

By Dr. Debu Tripathy

Video

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

Test May Predict Likelihood of Bladder Cancer Upstaging

February 11th 2025, 10:00pm

By Alex Biese

Article

The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

Breaking Down The Importance of Targeted Therapies in Colorectal Cancer Care

February 11th 2025, 8:00pm

By Dr. Suneel Kamath

Video

Dr. Suneel Kamath discusses the ALASCCA study in colorectal cancer and highlighted the importance of next-generation sequencing and testing.

Unexpected Support in Tough Times With Multiple Myeloma

February 11th 2025, 6:00pm

By Ronald Chin

Article

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

Explaining KRAS Mutations For Patients With Colorectal Cancer

February 11th 2025, 5:00pm

By Dr. Marwan Fakih

Video

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.